Bipolar Disorder
Out Of The Pipeline
Lumateperone for major depressive episodes in bipolar I or bipolar II disorder
Among patients with bipolar I or II disorder (BD I or II), major depressive episodes represent the predominant mood state when not euthymic, and...
Conference Coverage
When is your patient a candidate for ECT?
An emerging adjunct to ECT is cervical invasive vagus nerve stimulation (VNS) therapy, according to Dr. Mark S. George.
From the Journals
Ketamine fast, effective for suicidal crises
“The effect of ketamine is particularly marked among patients with a bipolar disorder,” said Dr. Fabrice Jollant of the University of Paris.
Opinion
Things reproductive psychiatrists might ‘always’ or ‘never’ do in 2022
In reproductive psychiatry, we tend to apply available data and clinical experience as we guide patients on a case-by-case basis.
From the Journals
Siblings of people with bipolar disorder have higher cancer risk
Findings may persuade clinicians to reevaluate the cancer risk among the unaffected siblings of patients with schizophrenia and bipolar disorder...
Families in Psychiatry
Family-oriented care in adult psychiatric residency
A family systems orientation is distinguished by its view of the family as a transactional system.
From the Journals
Stabilizing circadian rhythm tied to lower suicide risk in bipolar disorder
The therapeutic approach “could be adjunctive to further improve symptoms and reduce risk,” said Dr. Hilary P. Blumberg.
Feature
Despite the stigma, ECT remains a gold standard
For some patients, using electroconvulsive therapy as maintenance therapy makes sense, said Dr. Vaughn McCall.
Out Of The Pipeline
Olanzapine-samidorphan combination for schizophrenia or bipolar I disorder
Approved by the FDA on May 28, 2021, olanzapine-samidorphan combination (OSC) (Lybalvi, manufactured and distributed by Alkermes, Inc. Waltham, MA...
Commentary
Treating homeless patients: Book offers key insights
The book serves as a reminder for clinicians treating this population about why they continue to do this work, said Dr. Aislinn Bird.
FDA/CDC
FDA grants new indication to lumateperone (Caplyta) for bipolar depression
This makes lumateperone the only FDA-approved drug for adults with depressive episodes associated with bipolar I and II disorder.